ALNY Quote, Financials, Valuation and Earnings

Pfizer has a net margin of -14.12% compared to Alnylam Pharmaceuticals's net margin of 2.31%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

Alnylam Pharmaceuticals has a consensus price target of $304.87, signalling upside risk potential of 26.11%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 22.33%. Given that Alnylam Pharmaceuticals has higher upside potential than Pfizer, analysts believe Alnylam Pharmaceuticals is more attractive than Pfizer.

Alnylam Pharmaceuticals has a beta of 0.392, which suggesting that the stock is 60.76% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.6% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $593.2M, which are smaller than Pfizer quarterly revenues of $17.8B. Alnylam Pharmaceuticals's net income of -$83.8M is lower than Pfizer's net income of $410M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.73x versus 2.29x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -14.12% compared to Alnylam Pharmaceuticals's net margin of 24.22%. Alnylam Pharmaceuticals's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Alnylam Pharmaceuticals has a consensus price target of $304.87, signalling upside risk potential of 26.11%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 35.62%. Given that Regeneron Pharmaceuticals has higher upside potential than Alnylam Pharmaceuticals, analysts believe Regeneron Pharmaceuticals is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.392, which suggesting that the stock is 60.76% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $593.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Alnylam Pharmaceuticals's net income of -$83.8M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.73x versus 5.51x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -14.12% compared to Alnylam Pharmaceuticals's net margin of 24.16%. Alnylam Pharmaceuticals's return on equity of -- beat Sarepta Therapeutics's return on equity of 20.83%.

Alnylam Pharmaceuticals has a consensus price target of $304.87, signalling upside risk potential of 26.11%. On the other hand Sarepta Therapeutics has an analysts' consensus of $179.46 which suggests that it could grow by 82.43%. Given that Sarepta Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.392, which suggesting that the stock is 60.76% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.639%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $593.2M, which are smaller than Sarepta Therapeutics quarterly revenues of $658.4M. Alnylam Pharmaceuticals's net income of -$83.8M is lower than Sarepta Therapeutics's net income of $159M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 43.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.73x versus 5.77x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -14.12% compared to Alnylam Pharmaceuticals's net margin of 31.35%. Alnylam Pharmaceuticals's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -3.23%.

Alnylam Pharmaceuticals has a consensus price target of $304.87, signalling upside risk potential of 26.11%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.70 which suggests that it could fall by -1.24%. Given that Alnylam Pharmaceuticals has higher upside potential than Vertex Pharmaceuticals, analysts believe Alnylam Pharmaceuticals is more attractive than Vertex Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.392, which suggesting that the stock is 60.76% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $593.2M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Alnylam Pharmaceuticals's net income of -$83.8M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 13.73x versus 11.84x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.